Cell Reports (Nov 2023)

PD-L1-mediated immune evasion in triple-negative breast cancer is linked to the loss of ZNF652

  • Yuncheng Liu,
  • Yuan Peng,
  • Wei Du,
  • Chunyu Yu,
  • Zijun Peng,
  • Leyi Qin,
  • Yilei Ma,
  • Xin Wu,
  • Yani Peng,
  • Xiao Cheng,
  • Lu Xia,
  • Hangwei Fa,
  • Yuqing Wu,
  • Luyang Sun,
  • Jianying Liu,
  • Zhihua Liu,
  • Yongfeng Shang,
  • Shu Wang,
  • Jing Liang

Journal volume & issue
Vol. 42, no. 11
p. 113343

Abstract

Read online

Summary: The intrinsic regulation of programmed death ligand-1 (PD-L1) expression remains unclear. Here, we report that zinc-finger protein 652 (ZNF652) is a potent transcription repressor of PD-L1. ZNF652 frequently experiences loss of heterozygosity (LOH) in various cancers. Higher LOH rate and lack of estrogen-inducible transcription lead to suppressed expression of ZNF652 in triple-negative breast cancer (TNBC). Mechanistically, ZNF652 is physically associated with the NuRD transcription co-repressor complex to repress a cohort of genes, including PD-L1. Overexpression of ZNF652 inhibits PD-L1 transcription, whereas depletion of ZNF652 upregulates PD-L1. Loss of ZNF652 in TNBC unleashes PD-L1-mediated immune evasion both in vitro and in vivo. Significantly, ZNF652 expression is progressively lost during breast cancer progression, and a low ZNF652 level is correlated with elevated PD-L1 expression, less infiltrated CD8+ T cells, and poor prognosis in TNBC. Our study provides insights into PD-L1 regulation and supports the pursuit of ZNF652 as a potential biomarker and drug target for breast cancer immunotherapy.

Keywords